17 March 2016
Now available – videos from IntegraGen Genomics’ workshop during the 8th Congress of Human and Medical Genetics
16 February 2016
IntegraGen’s Scientific Advisory Board Meets to Review latest miR-31-3p data
IntegraGen’s oncology Scientific Advisory Board (SAB) recently met at the venue of the 2016 American Society of Oncology’s (ASCO) Gastrointestinal Cancers Symposium in San Francisco to review the results from the latest clinical study exploring the predictivity of miR-31-3p on the efficacy of anti-EGFR therapy in all-RAS wild-type metastatic colorectal cancer (…) »
14 January 2016
IntegraGen Reports 2015 Revenue
IntegraGen reports its 2015 Revenues : Strong cash position; Robust development of activity on genomic platforms; Lower revenue for genomic services business.
07 January 2016
IntegraGen Genomics to sponsor symposium on exome sequencing and RNA-SEQ during 8èmes Assises de Génétique Humaine et Médicale
IntegraGen Genomics will organize an educational luncheon symposium entitled “Exomes et RNASeq : de la recherche à la recherche clinique : challenges et perspectives” during the upcoming 8èmes Assises de Génétique Humaine et Médicale being held in Lyon, France. The program will be held from 12h45 to 13h45 on (…) »
02 December 2015
IntegraGen Collaborating with FIRE-3 Clinical Trial Investigators to Study hsa-miR-31-3p Metastatic Colorectal Cancer Biomarker
IntegraGen announced a collaboration with investigators from the FIRE-3 clinical trial (AIO KRK-0306) to further study the oncology biomarker hsa-miR-31-3p, a microRNA whose expression has been shown to be associated with anti-EGFR effect in patients with metastatic colorectal cancer (mCRC) treated with anti-EGFR therapy.
17 November 2015
Gustave Roussy and IntegraGen announce completion of 1,000 analyses with clinical research sequencing platform
Gustave Roussy and IntegraGen announced the achievement of one thousand genomic analyses utilizing their combined sequencing platform. The molecular profiles of cancer patients were analyzed as part of personalized medicine clinical trials being conducted at Gustave Roussy. The ability to deliver these results in less than three weeks (…) »
06 November 2015
Interview with Bernard Courtieu appears in La Tribune
Florence Pinaud’s interview with IntegraGen CEO Bernard Courtieu as a part of her story on newer genetic sequencing technologies, potential ethical issues associated with genetic sequencing, and the need for advanced data processing in association with these technologies appears (…) »
02 October 2015
IntegraGen Announces H1 2015 Financial Results
IntegraGen today announced its financial results for the 1st half of 2015 ending on 30 June 2015.
The financial statements were reviewed by the Company’s Board of Directors during a meeting held on 1 October, 2015.
28 August 2015
EEI-Biotech Finance interviews Bernard Courtieu
Bernard Courtieu, CEO of IntegraGen, is interviewed by EEI – Biotech for Finance. Mr. Courtieu discusses IntegraGen’s role in the sequencing of liver tumors as a part of a recent publication announcing the identification of a new virus involved in the development of liver cancer.
The interview (…) »
25 August 2015
Results from sequencing of 193 liver tumors performed by IntegraGen identifies potential role of a new virus in the development of liver cancer
IntegraGen announces a publication in Nature Genetics reporting the role of adeno-associated virus type 2 (AAV2) virus in the development of liver cancer. Professor Jessica Zucman-Rossi and her colleagues at Inserm Unit 1162 in Paris, supported by expert sequencing services from IntegraGen, identified the role of AAV2, a (…) »
